Grace Therapeutics, Inc (GRCE)
Grace Therapeutics, Inc. is a NASDAQ-listed common stock issue representing an operating company focused on pharmaceutical development and commercialization for rare and orphan diseases in Canada. The company’s pipeline includes GTX-104, an intravenous infusion candidate being developed for subarachnoid hemorrhage, as well as GTX-102, an oral mucosal spray of betamethasone aimed at improving neurological symptoms associated with Ataxia-Telangiectasia (A-T). Its portfolio also includes GTX-101, a topical bioadhesive film-forming polymer under development for pain linked to postherpetic neuralgia (PHN). Formerly known as Acasti Pharma Inc., the company adopted the Grace Therapeutics name in October 2024. Incorporated in 2002, Grace Therapeutics is headquartered in Princeton, New Jersey.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-GRCE
|
$2.40
|
12.2% Upside
|
Fair
|
$5.93
|
177.1% Upside
|
Bargain
|
Good
|
0.0%
|
November 13, 2026
|
0.9x
|
45.017 M
|
31.261 M
|
0.0%
|
73.6%
|
-10.9
|
50.9%
|
